GlassScriptPhysician profile
Gregory A Kendall
NPI 1912430216
$4,565.41
in general payments reported to CMS, 2019-2025
28 companies · $1,353 in 2025
The $1,353 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $31.46 · 2021: $253 · 2022: $282 · 2023: $1,702 · 2024: $943 · 2025: $1,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,898 · Travel and Lodging: $1,090 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.35 |
| Travel and Lodging | $1,089.71 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,105.15 | 2021-2023 | Achieve |
| Novartis Pharmaceuticals Corporation | $401.74 | 2023-2025 | |
| Boston Scientific Corporation | $337.28 | 2022-2025 | Bodyguardian, Cds - Mct/Cem Monitoring |
| E.R. Squibb & Sons, L.L.C. | $308.99 | 2024-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.07 | 2024-2025 | Jardiance |
| Pfizer INC. | $190.82 | 2024-2025 | |
| Cvrx, INC. | $182.24 | 2023-2025 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $176.49 | 2023-2024 | Inpefa |
| Amgen INC. | $168.58 | 2024-2025 | Repatha |
| Merck Sharp & Dohme LLC | $161.14 | 2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $157.62 | 2022-2024 | Lifevest |
| Abbott Laboratories | $155.55 | 2021-2022 | |
| Atricure, INC. | $150.56 | 2024-2025 | Atricure Cryoice Cryoablation System (Cryo2), Synergy Ablation System, Atriclip Laa Exclusion System |
| Novo Nordisk INC | $149.04 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $98.82 | 2023 | Impella |
| Janssen Scientific Affairs, LLC | $80.15 | 2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $65.84 | 2025 | Onpattro, Amvuttra |
| Esperion Therapeutics, INC. | $62.73 | 2023-2025 | Nexletol |
| Lantheus Medical Imaging, INC. | $48.42 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $43.46 | 2023 | Xarelto |
| Scpharmaceuticals INC. | $40.19 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $36.24 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $22.90 | 2022 | |
| Inspire Medical Systems, INC. | $21.69 | 2025 | Inspire |
| Agepha Pharma Fz LLC | $19.97 | 2024 | Lodoco |
| Kiniksa Pharmaceuticals, LTD. | $19.00 | 2023 | Arcalyst |
| Medicomp INC | $18.74 | 2025 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Kendall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.